Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization

Richard Huang , Derek Smith (1) , Catherine Le , Wen-Wei Liu , Ellen Ordinario , Chitra Manohar , Michael Lee , Jaya Rajamani , Huan Truong , Jing Li (2) , Cindy Choi (3) , Jingchuan Li , Amrita Pati , Lukas Bubendorf , Reinhard Buettner (4) , Keith Kerr (5) , Fernando Lopez-Rios (6) , Antonio Marchetti (7) , Ivonne Marondel , Andrew G. Nicholson (8) , Ayşim Büge Öz , Patrick Pauwels , Frédérique Penault-Llorca (9, 10) , Giulio Rossi , Erik Thunnissen (11) , Amy Hanlon Newell , Greg Pate , Ina Menzl

1 UVic-Genome BC Proteomics Centre - Genome British Columbia Proteomics Centre [Victoria]
2 SWJTU - Southwest Jiaotong University
3 US Department of Energy Joint Genome Institute
4 Institute of Pathology
5 Department of Pathology
6 Laboratorio de Dianas Terapeuticas
7 Unit of Molecular Pathology
8 Department of histopathology
9 UNICANCER/CJP - Centre Jean Perrin [Clermont-Ferrand]
10 IMoST - Imagerie Moléculaire et Stratégies Théranostiques
11 Department of Pathology

The ability to determine ROS1 status has become mandatory for patients with lung adenocarcinoma, as many global authorities have approved crizotinib for patients with ROS1-positive lung adenocarcinoma.

Domaines: Sciences du Vivant [q-bio]; Cancer

Richard Huang, Derek Smith, Catherine Le, Wen-Wei Liu, Ellen Ordinario, et al.. Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization. Archives of Pathology and Laboratory Medicine, 2020, 144 (6), pp.735-741. ⟨10.5858/arpa.2019-0085-OA⟩. ⟨hal-02882275⟩